The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 08, 2025

Filed:

Nov. 21, 2022
Applicant:

Teclison, Inc., Princeton, NJ (US);

Inventor:

Ruey-min Lee, Short Hills, NJ (US);

Assignee:

TECLISON, INC., Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/53 (2006.01); A61K 31/05 (2006.01); A61K 31/09 (2006.01); A61K 31/136 (2006.01); A61K 31/27 (2006.01); A61K 31/352 (2006.01); A61K 31/485 (2006.01); A61K 35/17 (2025.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/53 (2013.01); A61K 31/05 (2013.01); A61K 31/09 (2013.01); A61K 31/136 (2013.01); A61K 31/27 (2013.01); A61K 31/352 (2013.01); A61K 31/485 (2013.01); A61K 35/17 (2013.01); A61K 39/395 (2013.01); A61K 39/39541 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); C07K 2317/73 (2013.01);
Abstract

Disclosed herein are methods and compositions for enhancing an immune response to a solid tumor in a subject. In some embodiments, a method comprises: (a) administering to the subject a hypoxia-activated bioreductive agent (HABA); (b) inducing hypoxia by (i) administering a hypoxia-inducing agent to the subject or (ii) embolizing one or more blood vessels supplying the solid tumor; and (c) administering an immune checkpoint inhibitor prior to, simultaneously with, or subsequent to step (b) in an amount effective to enhance an immune response to the solid tumor, as compared to an immune response in the absence of the immune checkpoint inhibitor. Kits for use in the disclosed methods are also provided.


Find Patent Forward Citations

Loading…